MX2011007371A - Metodo para tratar la hiperglucemia con la molecula. - Google Patents

Metodo para tratar la hiperglucemia con la molecula.

Info

Publication number
MX2011007371A
MX2011007371A MX2011007371A MX2011007371A MX2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A MX 2011007371 A MX2011007371 A MX 2011007371A
Authority
MX
Mexico
Prior art keywords
glp
treating hyperglycemia
diabetes
diketopiperazine
administered
Prior art date
Application number
MX2011007371A
Other languages
English (en)
Inventor
Peter Richardson
Donald Costello
Robert A Baughman
Mark T Marino
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2011007371A publication Critical patent/MX2011007371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un método para tratar la hiperglucemia y/o diabetes en un sujeto. En particular, el método está dirigido a un tratamiento de pacientes con diabetes melitus tipo 2 quienes tienen una concentración de glucosa en la sangre en ayunas mayor de aproximadamente 8 mM, en donde el paciente es administrado con una formulación que comprende una molécula GLP-1 y una dicetopiperazina mediante inhalación pulmonar con un sistema de inhalación de polvo seco.
MX2011007371A 2009-01-08 2010-01-08 Metodo para tratar la hiperglucemia con la molecula. MX2011007371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14335809P 2009-01-08 2009-01-08
PCT/US2010/020448 WO2010080964A1 (en) 2009-01-08 2010-01-08 Method for treating hyperglycemia with glp-1

Publications (1)

Publication Number Publication Date
MX2011007371A true MX2011007371A (es) 2011-09-06

Family

ID=41820660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007371A MX2011007371A (es) 2009-01-08 2010-01-08 Metodo para tratar la hiperglucemia con la molecula.

Country Status (11)

Country Link
US (1) US9078866B2 (es)
EP (2) EP2853268A1 (es)
JP (2) JP5918539B2 (es)
AU (2) AU2010203573A1 (es)
CA (1) CA2749099A1 (es)
DK (1) DK2379100T3 (es)
ES (1) ES2529100T3 (es)
MX (1) MX2011007371A (es)
PT (1) PT2379100E (es)
SI (1) SI2379100T1 (es)
WO (1) WO2010080964A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CN101969927A (zh) * 2007-10-24 2011-02-09 曼金德公司 预防glp-1不良影响的方法
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010105094A1 (en) 2009-03-11 2010-09-16 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
BR112015004418A2 (pt) * 2012-08-29 2017-07-04 Mannkind Corp composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit.
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102246914B1 (ko) 2013-03-15 2021-04-30 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
DE202016104106U1 (de) 2015-08-07 2016-10-09 Hitachi Koki Co., Ltd. Elektrowerkzeug

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
KR20010073033A (ko) 1998-08-28 2001-07-31 피터 지. 스트링거 인슐리노트로픽 펩티드의 투여 방법
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
BR0107837A (pt) 2000-01-27 2003-01-14 Lilly Co Eli Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
EP1301187B1 (en) 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20050265927A1 (en) 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
CA2589118A1 (en) 2004-12-03 2006-06-08 Mederio Ag A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
JP2008526893A (ja) * 2005-01-10 2008-07-24 マンカインド コーポレイション 肺における吸入可能なインスリンの自然増加を最少化するための方法及び組成物
CA2617226A1 (en) * 2005-08-01 2007-02-08 Mannkind Corporation Method of preserving the function of insulin-producing cells
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
KR20150042304A (ko) * 2006-04-14 2015-04-20 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
RU2467741C2 (ru) 2007-10-24 2012-11-27 Маннкайнд Корпорейшн Доставка активных веществ
CN101969927A (zh) 2007-10-24 2011-02-09 曼金德公司 预防glp-1不良影响的方法

Also Published As

Publication number Publication date
AU2016200249A1 (en) 2016-02-04
US20120094905A1 (en) 2012-04-19
JP2015157817A (ja) 2015-09-03
CA2749099A1 (en) 2010-07-15
SI2379100T1 (sl) 2015-02-27
EP2379100B1 (en) 2014-11-12
EP2853268A1 (en) 2015-04-01
HK1164112A1 (en) 2012-09-21
DK2379100T3 (en) 2014-12-01
EP2379100A1 (en) 2011-10-26
JP2012514646A (ja) 2012-06-28
US9078866B2 (en) 2015-07-14
JP5918539B2 (ja) 2016-05-18
WO2010080964A1 (en) 2010-07-15
ES2529100T3 (es) 2015-02-16
AU2010203573A1 (en) 2011-06-30
PT2379100E (pt) 2015-02-09

Similar Documents

Publication Publication Date Title
MX2011007371A (es) Metodo para tratar la hiperglucemia con la molecula.
Cramer et al. Effects of yoga on cardiovascular disease risk factors: a systematic review and meta-analysis
MX2007012102A (es) Control superior de glucosa en la sangre en tratamiento de diabetes.
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
JP2013541576A5 (es)
PL2211842T3 (pl) Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym
WO2007139941A3 (en) Composition and methods for treatment of congestive heart failure
FI3524261T3 (fi) Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
Enginyurt et al. The role of pure honey in the treatment of diabetes mellitus
JP2011105610A5 (es)
WO2007076505A3 (en) Transferrin and transferrin-based compositions for diabetes treatment
SG159462A1 (en) Multi-herbal medicinal composite for treating the metabolic syndrome and preparation method thereof
England et al. Efficacy, Safety And Tolerability Of Inhaled Dry Powder Insulin (Exubera®) In Adult Diabetics With Asthma
WO2009057461A1 (ja) 糖尿病治療剤
ZHANG Clinical curative effect of captopril combined with nifedipine sustained-release tablets in the treatment of hypertension in patients with type 2 diabetes
ZHANG et al. The inspection of sitagliptin to metabolic index and carotid artery IMT in metabolic syndrome patients with type 2 diabetes
LAO et al. Cinical observation of insulin detemir combined with acarbose in curing type 2 diabetic patients
Agarwal et al. Study of optimal basal insulin glargine dose requirement in Indian population as an add on therapy to oral hypoglycaemic agents to achieve target fasting blood glucose levels
YE et al. Observation of the curative effect of insulin human analog in the application on diabetic patients during perioperative period
Aloi et al. Use of the eGlycemic Management System by Glytec Provides Safe and Effective Glucose Control for Cardiac Surgery Patients Managed on Intravenous Insulin Therapy
ZHANG et al. Efficacy of continuous glucose monitoring system combined with insulin pump in diabetic pafients aged 60 years and over
Sukhinina et al. Effektivnost'ispol'zovaniya interval'noy gipoksicheskoy trenirovki v sochetanii s apparatnymtraktsionnym metodom v reabilitatsionnoy programme patsientov s degenerativno-distroficheskimizabolevaniyami pozvonochnika
Samaria et al. Mechanical Ventilation and In-Hospital Mortality in Patients of Acute Exacerbation of COPD (AECOPD) on Conventional Treatment Versus Non Invasive Positive Airway Pressure (NIPPV).
Nechevska et al. P1270 THE EFFECT OF GLARGINE AND NPH INSULIN IN PATIENTS WITH DIABETES MELLITUS TYPE 2

Legal Events

Date Code Title Description
FG Grant or registration